Abstract: Compositions comprising fatty acid analogs are provided for treating metabolic syndrome, anemia, cancer, cardiovascular disease, diabetes, dyslipidemia, hypertension, inflammation, insulin resistance, prediabetes, fatty liver disease, steatohepatitis, iron overload, neurodegenerative diseases, including Alzheimer's disease and other forms of dementia, and other related conditions. Methods for the diagnosis and monitoring of metabolic syndrome and other conditions are also provided.

Abstract: Novel, antitumor treatment methods and related products, in particular, novel, combinatorial antitumor treatment methods and related compositions including (1) cisplatin, or other platinum-based drug, and (2) 4-(phenylthio)butanoic acid (PTBA) or a prodrug of 4-(phenylthio)butanoic acid (PTBA), and kits, systems, or treatment protocols comprising the same, and methods of manufacturing and using the same, particularly for use in cancer or tumor treatment, and specifically, co-administration of (1) cisplatin, or other platinum-based drug, and (2) 4-(phenylthio)butanoic acid (PTBA) or a prodrug of 4-(phenylthio)butanoic acid (PTBA), to cancer patients.

Abstract: The present invention relates to a novel mixed glycerol ester composition comprising glycerol ester molecules comprising both valeric acid moieties and lauric acid moieties in the same molecule. The mixed glycerol ester composition can be useful for mitigating moderate to severe gut health challenges in animals and, in particular, it has shown to be effective for alleviating and/or mitigating coccidiosis in poultry. The present invention also relates to an animal feed additive comprising said mixed glycerol ester composition and to the use of said animal feed additive for improving the feed conversion ratio of animals.

Abstract: The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia.

Abstract: A compound of furancarboxylic acids used in the preparation of an additive for an animal feed for improving the performance of an animal is provided. The compound of furancarboxylic acids is according to Formula (I), wherein each of R1, R2 and R3 is independently H or —COOH. The compound of furancarboxylic acids or a feed-acceptable salt thereof improves the performance of livestock, poultry, and aquaculture animals.

Abstract: The present invention relates to a method of treating serotonin reuptake inhibitor withdrawal syndrome comprising the administration of a therapeutically effective amount of escitalopram gentisate.

Abstract: A method of treating a pediatric cancerous solid tumor in a mammalian subject is disclosed that comprises intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor. Another contemplated method comprises the steps of intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor and systemically administering a tumor-inhibiting effective amount of a systemic anti-cancer medication that provides synergistic cytotoxicity with the halogenated xanthene. The two administrations can occur concurrently, or one prior to the other.

Abstract: Compositions are provided for the liquid oral administration of topiramate and its salts. The invention further provides methods for treating diseases and disorders using the compositions.

Abstract: The present invention aims to provide a novel AMP-activated protein kinase activator. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, or a hydrate thereof. In addition, the present invention relates to an AMP-activated protein kinase activator containing the aforementioned compound, and a medicament containing the aforementioned compound for the prophylaxis and/or treatment of cancer.

Abstract: The present invention relates to a compound or pharmaceutically acceptable salts thereof, that modulates NLRP3 in that the NLRP3 inflammasome is activated. This invention further relates to the compounds and/or compositions for use in the prevention and treatment of a condition, disease or a disorder by activating the NLRP3 inflammasome, wherein the disease is selected from a group comprising infectious diseases, or cancer. Moreover, the invention relates to the use of the present compounds for analyzing a the activity of NLRP3 activation.

Abstract: Disclosed are combination therapies including administration of I-DASH inhibitors and PGE2 antagonists, and the use of such therapies in the treatment of cell proliferative diseases.

Abstract: Provided is a composition for use in treating a skin condition, the composition comprising: (a) a first component comprising a substituted or unsubstituted diindolylmethane compound; and (b) a second component comprising a substituted or unsubstituted retinoid compound.

Abstract: This application describes methods of inhibiting APOL1 and treating APOL1-mediated diseases comprising administering Compound I and/or a pharmaceutically acceptable salt thereof. The application also describes pharmaceutical compositions comprising Compound I and/or a pharmaceutically acceptable salt thereof.

Abstract: Provided are methods useful in the prophylaxis or treatment of an S1P1 modulated disease in different populations of individuals, including those with hepatic impairment. In some methods, etrasimod is prescribed or administered to an individual in need of treatment wherein the dose is not adjusted for the patient having mild, moderate, or severe hepatic impairment.

Abstract: This disclosure in general describes a pharmaceutical kit for treating colorectal cancer; the pharmaceutical kit comprises (E)-N-hydroxy-3-(1-(phenylsulfonyl)-indolin-5-yl)-acrylamide, and an anti-PD-1 or anti-PD-L1 antibody. Furthermore, this disclosure describes a method for treating colorectal cancer in a subject, comprising administering to the subject the aforementioned pharmaceutical kit, wherein the (E)-N-hydroxy-3-(1-(phenylsulfonyl)-indolin-5-yl)-acrylamide is given to the subject in a dosage ranging from about 10 ?g/kg to 1 g/kg; and the anti-PD-1 or anti-PD-L1 antibody is administered to the subject at a dosage ranging from about 1 ?g/kg to 100 mg/kg.

Abstract: Provided herein are compositions and methods for the treatment of sexual dysfunction and related diseases, disorders, and conditions. An aspect of the present disclosure is a combination comprising at least two compounds independently selected from empathogens, stimulants, and tryptamines. In particular, the combinations disclosed relate to the empathogen (or entactogen) 1-(benzofuran-5-yl)-N-methylpropan-2-amine (5-MAPB) combined a tryptamine, such as 4-Acetoxy-N-methyl-N-allyltryptamine (4-AcO-MALT) or 4-Acetoxy-N-methyl-N-ethyltryptamine (metacetin or 4-AcO-MET), and a stimulant, such as 4-fluoromethylphenidate (4F-MPH), 2-fluoromethamphetamine (2-FMA), or 4-fluoromethamphetamine (4-FMA). The combinations disclosed herein can be utilized to augment and support sexual intimacy between mammals, particularly humans. In addition to augmenting sexual intimacy, the combinations disclosure herein can be used to treat sexual disorders.

Abstract: Provided are allyl tryptamines, such as asymmetric allyl tryptamines. In some embodiments, such compounds modulate the activity of monoamine receptors and/or monoamine transporters. Also provided are methods for the preparation of allyl tryptamines and pharmaceutical compositions thereof. Methods of using the allyl tryptamines, alone or in combination with other therapeutic agents, are provided. In some embodiments, allyl tryptamines are used to treat CNS disorders, such as mental health conditions and neurodegenerative disorders, or are used for the improvement of mental health or functioning.

Abstract: The present invention relates to treatment of subgroups of cancer patients, methods for identifying treatment and dosage regimens, as well as methods for identifying these subgroups of cancer patients.

Abstract: The invention features dosing regimens and pharmaceutical formulations for oral administration of palovarotene. The dosing regimens can reduce heterotopic ossification, reduce the number of flare-ups, and/or reduce the severity of flare-ups in subjects suffering from fibrodysplasia ossificans progressiva.

Abstract: Disclosed herein are formulations of histamine and histamine receptor agonists for treating a cancer or a tumor. Also disclosed are methods of using myeloid derived suppressor cell (MDSC) detection assays to select cancer patients for treatment with the formulations as disclosed herein. Also disclosed are methods of restoring the immune response against tumors in cancer patients who are incomplete responders to immune checkpoint inhibitor (ICI) therapy.

Abstract: Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.

Abstract: Methods of safely administrating a matrix metalloproteinase 12 (MMP-12) inhibitor by oral administration are described. Also described are methods for providing clinically proven safe treatment of asthma, chronic obstructive pulmonary disease (COPD), or pulmonary fibrosis, by oral administration of an MMP-12 inhibitor.

Abstract: Compositions and methods are provided that are useful for diagnosing, treating, and monitoring alcohol dependence and disorders, susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders. The methods include treating patients with an antagonist of the serotonin receptor 5-HT3 for such disorders, wherein the patient's serotonin transporter gene SLC6A4 is known to have particular genotypes.

Abstract: Compounds, compositions, and methods are provided for covalently linking an antibody or an antibody fragment to a cargo molecule, such as a therapeutic or a diagnostic agent, using a combination of enzymatic glycan remodeling and click chemistry. The method allows a cargo molecule to be selectively and efficiently attached post-translationally to an antibody or an antibody fragment. Also provided are antibody drug conjugates, methods of making, and uses thereof.

Abstract: Provided herein are methods for treating behavior alterations using KDM1A inhibitors, particularly 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine.

Abstract: The present application relates to topical formulations comprising Compound-I or its free base, and a second active agent selected from nicotinic acid, nicotinamide, and vitamin K, and a combination thereof, for treating ocular neovascularization. The present application also relates to pharmaceutical compositions comprising particles of Compound-I or its free base, and suspension formulations comprising the particle compositions of Compound-I or its free base.

Abstract: A pharmaceutical composition for modified release, comprising (1) (R)-2-(2-aminothiazol-4-yl)-4?-[2-((2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 10 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mPa's or more at a 5% aqueous solution at 25 C is disclosed.

Abstract: Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.

Abstract: The present disclosure provides a salt form and a crystal form of a sulfonylurea ring substituted compound and a specific crystal form A thereof, and also provides an application thereof in preparation of medicaments for treating bacterial infection-related diseases. The crystal form A of the compound is easy to obtain and has good physical stability and chemical stability, with high industrial application value and economic value. The compound of the present disclosure has good water solubility, suitable for intravenous administration, and excellent in pharmacokinetic properties; has good safety; has good efficacy, and will be used for treatment of bacterial infection-related diseases.

Abstract: The current invention is in the field of molecular biology/pharmacology and provides methods of using compounds that modulate the effects of GPR30/GPER for treating obesity and diabetes (preferably agonists) as well as disease states and/or conditions that result from excessive formation of reactive oxygen species (preferably antagonists). These compounds may function as agonists and/or antagonists of the disclosed estrogen receptor and/or modulate the expression/upregulation of nox and nox-associated reactive oxygen species (ROS).

Abstract: Disclosed herein are novel formulations containing relacorilant ((R)-(1-(4-fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone) that are suitable for administration, including oral administration, to patients suffering from disorders amenable to treatment by glucocorticoid receptor modulators (GRMs). Single unit dosage forms comprise softgel capsules containing these formulations. Such softgel capsules may contain, e.g., relacorilant formulations containing 25 milligrams (mg), 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, or other amounts of relacorilant. These novel formulations and single unit dosage forms may be used to treat diseases and disorders including Cushing's syndrome, Cushing's Disease, and other disorders.

Abstract: The invention provides a p38 MAPK inhibitor of Formula I, or a pharmaceutically acceptable salt or solvate thereof: for use in the treatment or prevention of hypercytokinemia in a human patient; wherein R is C1-3alkyl, optionally substituted by one or more halo, NR1R2 or hydroxy, and R1 and R2 are independently H, halo or C1-3alkyl, optionally substituted by one or more F. Also provided are compositions for use in the treatment or prevention of hypercytokinemia comprising the p38 MAPK inhibitor of Formula I; and methods for treating or preventing hypercytokinemia in a human patient in need thereof comprising administering to the patient a therapeutically or prophylactically effective amount of a p38 MAPK inhibitor of Formula I. The invention also provides a p38 MAPK inhibitor and an antimicrobial agent, such as an antiviral agent, for use in the treatment or prevention of hypercytokinemia.

Abstract: The invention disclosed herein relates to synergistic bioactive compositions for inhibiting vascular calcification. Particularly, the present invention relates to exogenous blend of magnesium 2-acetylamino ethane sulfonic acid and 2-methyl-4-aminomethyl-5-hydroxymethyl-3-pyridinol and salts thereof which are present in the weight ratio of 1:0.002 to 1:1.8 along with pharmaceutically acceptable excipients. More particularly, the synergistic composition is useful for treating cardiovascular diseases and renal vascular diseases.

Abstract: It relates to a method of treating a subject with liver fibrosis and/or liver cirrhosis. The disclosure provides a pharmaceutical composition that includes hydronidone or a salt thereof that can be used for treating a subject with liver fibrosis and/or liver cirrhosis. Liver stiffness measurements values and/or Ishak scores may be used to identify subjects for treatment of liver fibrosis and/or liver cirrhosis.

Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof:

Abstract: CCR2 is involved in the regulation of normal cardiovascular function and during the cardiovascular stress response to hemorrhagic shock and fluid resuscitation. Disclosed herein are methods of using CCR2 inhibitors to reduce fluid requirements and to prevent death from hemodynamic decompensation during resuscitation.

Abstract: Veterinary pharmaceutical compositions for direct systemic introduction, also known as DSI pharmaceutical compositions. One veterinary pharmaceutical composition for direct systemic introduction includes about 10-17 dry mass % bovine gelatin; about 10-17 dry mass % mannitol; about 0-1 dry mass % of a surfactant; and about 65-80 dry mass % of the active pharmaceutical ingredient which is a proton pump inhibitor. A method of manufacturing a veterinary pharmaceutical composition for direct systemic introduction includes combining one or more pharmacologically inactive compounds to form a first solution; using one or more surfactants to form a second solution; adding an active pharmaceutical ingredient to the second solution to form a first mixture; adding the first solution to the first mixture to form a pre-formulation; freezing the pre-formulation; and lyophilizing the pre-formulation.

Abstract: Pituitary tumors may be reduced in size by administration of relacorilant. Pituitary tumors include, without limitation, non-secreting tumors, hormone-secreting tumors, adenomas, and carcinomas. Relacorilant administration may be effective to reduce hormone secretion from a hormone-secreting pituitary tumor, e.g., to reduce adrenocorticotrophic hormone (ACTH) secretion. A pituitary tumor may be imaged before and/or after relacorilant administration. Relacorilant may be administered independent of surgery, and before, during, or after surgery to treat a pituitary tumor. Relacorilant may aid or improve surgical outcomes, and may reduce the size or growth of pituitary tumor tissue before surgery, and any tumor tissue remaining following surgical treatment. Relacorilant may be orally administered for the treatment of pituitary tumors. Relacorilant may be orally administered to a fasted patient, or to a fed patient.

Abstract: Provided are methods of treating a patient diagnosed with Fabry disease and methods of enhancing ?-galactosidase A in a patient diagnosed with or suspected of having Fabry disease. Certain methods comprise administering to a patient a therapeutically effective dose of a pharmacological chaperone for ?-galactosidase A, wherein the patient has a mutation in the nucleic acid sequence encoding ?-galactosidase A. Also described are uses of pharmacological chaperones for the treatment of Fabry disease and compositions for use in the treatment of Fabry disease.

Abstract: The invention concerns the use of compounds represented by formula (I) as inotropic agents. The compounds of formula (I), which include, as preferred, 1-[(1S)-1-(2,3-dichloro-4-methoxyphenypethyl]-3-methyl-3-[(4R)-1-methyl-3,3-dimethyl-4-piperidyl]-urea and its hydrochloride salt, are herein reported to have a significant inotropic activity on cardiomyocytes from both normal and myocardial infarction-induced heart failure animal models, which makes them useful for treating cardiovascular patients in need thereof. Differently from known inotropic agents, the present compounds are effective on cardiomyocyte contractility without influencing calcium mobilization. Accordingly, they are advantageously free from adverse effects caused by increased calcium concentrations, such as increased oxygen demand, tachycardia, arrhythmia, ischemia, etc. Overall, a new, safe and effective inotropic treatment is thus made available.

Abstract: Described herein are methods of treating an autoimmune benign hematological disorder (e.g., ITP, CAD, wAIHA, and TTP) with the Factor B inhibitor LNP023 (iptacopan) or a pharmaceutically acceptable salt thereof, e.g. iptacopan hydrochloride.

Abstract: The present invention relates to new uses of a 5-HT4 receptor agonist, specifically Isopropyl-3-{5-[1-(3-methoxypropyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole (Compound-1) or a pharmaceutically acceptable salts thereof, for the treatment of dementia due to menopause, senile dementia, cognitive deficits associated with schizophrenia, depression, chemotherapy-induced cognitive impairment, and behavioral and psychological symptoms of dementia such as apathy/indifference, agitation, aggression, depression, anxiety, irritability/lability, dysphoria, aberrant motor behavior, delusions, hallucinations, elation/euphoria, psychosis, disinhibition, sleep and night time behavior disorders or appetite and eating disorders. The present invention further provides use of the said compounds in the manufacture of medicament intended for the treatment of the disorders described herein.

Abstract: Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica, or Cannabis ruderalis, optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients. In another aspect, tryptamine compositions described herein enhance neuroplasticity by promoting neuronal branching through the formation of neurites (i.e.

Abstract: The present invention relates to 1,2-dihydroquinoline-2-ones of formula (I): or a pharmaceutically acceptable salt or solvate thereof, for its use in the treatment of limb girdle muscular dystrophy.

Abstract: A pharmaceutical composition containing tasquinimod or a pharmaceutically salt of tasquinimod, a method for assessment thereof and a process for its manufacture. The use in therapy of a pharmaceutical composition containing tasquinimod or a pharmaceutically acceptable salt of tasquinimod. The compound 3,3?-methylenebis(4-hydroxy-5-methoxy-1-methylquinoline-2(1H)-one) and its use in a method for assessing a pharmaceutical composition containing tasquinimod or a pharmaceutically acceptable salt of tasquinimod.

Abstract: Provided herein are compounds of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes.

Abstract: FoxO inhibitors for use in the treatment of diseases caused by abnormal TDP-43 and/or FUS proteins. The present invention refers to FoxO inhibitors, preferably quinolone derivatives, for use in the treatment of diseases caused by alterations of TDP-43 and/or FUS proteins, preferably Amyotrophic lateral sclerosis (ALS).

Abstract: The present disclosure relates to methods of treating a disease (e.g., a seizure) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of tezampanel, a pharmaceutically acceptable salt thereof, or a prodrug thereof, alone or in combination with a therapeutically effective amount of a benzodiazepine, a pharmaceutically acceptable salt thereof, or a prodrug thereof.

Abstract: The present disclosure relates to methods of treating or preventing a condition (e.g., a symptom associated with opiate withdrawal or opiate relapse) in a subject, comprising administering to the subject a therapeutically effective amount of tezampanel, a pharmaceutically acceptable salt thereof, or a prodrug thereof.

Abstract: The disclosure provides methods of inhibiting human aldosterone synthase, treating hypertension, or treating primary aldosteronism in a subject in need thereof, comprising administering an effective amount of (R)-Compound 1 to the subject, wherein (R)-Compound 1 is: Formula (I).